• Pazopanib Hydrochloride: Readouts That Resolve Response

  2026-09-22

  Pazopanib Hydrochloride is a powerful model for studying how kinase inhibition produces growth arrest, cell death, and anti-angiogenic effects. This article applies a response-phenotyping framework to GW786034 experiments, helping researchers select more informative assays than viability alone.

• Dual HER2–VEGFR2 Targeting in TNBC

  2026-09-22

  The reference study evaluates lapatinib and Telatinib as a dual tyrosine kinase inhibition strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Its phenotype-centered results link treatment with reduced proliferation, invadopodia formation, and two-dimensional angiogenic tube formation, while leaving target engagement, pharmacological synergy, and in vivo efficacy unresolved.

• Chrysin Sensitizes RCC to Sunitinib via Ferroptosis

  2026-09-21

  A November 2025 study reports that chrysin increases renal cell carcinoma sensitivity to Sunitinib by suppressing PI3K/Akt signaling and reducing SLC7A11 and GPX4, thereby promoting ferroptosis. Its combination of network pharmacology, molecular docking, functional assays, and pathway-rescue experiments provides a mechanistic framework for studying Sunitinib resistance, while remaining preclinical and primarily cell-based.

• Phosbind Acrylamide: Reading Phosphorylation States

  2026-09-21

  Phosbind Acrylamide enables antibody-free protein phosphorylation analysis by converting phosphate-dependent binding into measurable SDS-PAGE mobility shifts. This guide explains the chemistry, assay decisions, and HBV capsid workflow that determine when phosphate-affinity electrophoresis is most informative.

• AAL-993: From VEGFR Potency to Assay Design

  2026-09-20

  AAL-993 is a selective VEGF receptor inhibitor with a distinctive VEGFR-2/3 potency profile. This article explains how to use it as a causal validation tool alongside network pharmacology in tumor angiogenesis research.

• CFDA SE Cell Tracer Kit: Practical Guide

  2026-09-19

  The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for cell proliferation studies, cell lineage tracing, and live-cell tracking. It is appropriate when covalent labeling must remain detectable for several days, but not when reversible marking, rapid dye clearance, or immediate physiological readouts are required.

• WST-8 Glucose Uptake Assay Kit Guide

  2026-09-18

  The WST-8 Glucose Uptake Assay Kit is a non-radioactive glucose uptake assay based on 2-deoxyglucose conversion, NADPH generation, and 450 nm formazan detection. Product information reports a working linearity of 10–500 μM under stated assay conditions, supporting quantitative cellular glucose metabolism studies.

• Beyond Viability: Measuring Cancer Drug Responses

  2026-09-18

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of an in vitro drug response. The framework encourages cancer researchers to combine endpoint and time-course measurements so that cytostatic effects are not mistaken for cell killing.

• Balsalazide in Active Ulcerative Colitis: Evidence Review

  2026-09-17

  This 2009 review examined balsalazide as a colon-targeted 5-aminosalicylate prodrug for mild-to-moderate active ulcerative colitis. Its central finding was that bacterial activation in the colon supports sustained 5-ASA delivery, with clinical evidence for remission induction, rapid symptom improvement, and tolerability comparable to other oral 5-ASA therapies.

• EdU Imaging Kits (Cy3): S-Phase Detection

  2026-09-17

  EdU Imaging Kits (Cy3) provide antibody-free detection of DNA synthesis during S phase through copper-catalyzed click chemistry. The 5-ethynyl-2'-deoxyuridine imaging kit supports fluorescence microscopy and flow cytometry while preserving morphology and antigen-accessible epitopes.

• Pazopanib in ATRX-Aware Glioma Assays

  2026-09-16

  Pazopanib (GW-786034) offers a powerful way to study RTK dependence, angiogenesis inhibition, and genotype-specific drug response in glioma models. This guide translates ATRX-focused evidence into assay decisions that distinguish cell-autonomous toxicity from vascular effects.

• PD 173074: FGFR1 Workflows for Cancer Research

  2026-09-16

  PD 173074 enables pathway-resolved testing of FGFR1-driven growth, fibroblast-mediated drug rescue, and VEGFR2-linked angiogenesis. This practical guide translates ESCC microenvironment findings into dose-finding, co-culture, signaling, and troubleshooting workflows.

• Better In Vitro Cancer Drug Response Evaluation

  2026-09-15

  Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating growth inhibition from cell killing, the work provides a more interpretable framework for cancer research, assay design, and drug-response profiling.

• Sunitinib Workflows for RCC Resistance Research

  2026-09-15

  Build more informative Sunitinib experiments by pairing RTK pathway inhibition with apoptosis, cell-cycle, angiogenesis, and metabolic readouts. This workflow translates recent renal cell carcinoma resistance findings into practical combination assays, controls, and troubleshooting decisions.

• CH 223191: Dissecting AhR Context in Toxicology

  2026-09-14

  CH 223191 is an aryl hydrocarbon receptor antagonist for separating harmful AhR activation from context-dependent physiological signaling. This article connects dioxin toxicology with microbiota–tryptophan–AhR biology and translates that distinction into better assay design.

8368 records 1/558 page Next 12345 下5页 Last page